In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...

Truist analyst Joon Lee keeps a Buy rating and $150 price target on Axsome Therapeutics (AXSM) while noting that the firm is an “aggressive buyer” of the stock after the “positive” Phase 3 results in ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $139.75, along ...

Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $122 from $124 and keeps an Outperform rating on the shares after the ...

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease ...